BridgeBio Cardiorenal chief medical officer Dr Jonathan Fox stated: “The EU approval of acoramidis is a significant ...

Nearly 3 months after the FDA green-lit the TTR stabilizer, it joins tafamidis as the second therapy in Europe for the ...

The EU is the second market for the drug after the US, where it was approved under the Attruby brand name last November, on ...

ATTR amyloidosis is an autosomal-dominant hereditary disease caused by various point mutations of transthyretin (TTR), or is a disease of the very old (senile type). Transthyretin is almost ...

The approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most ...

While healthy transthyretin moves hormones through blood and spinal fluid, misfolded versions of the protein form dangerous clumps in the heart and along nerves—triggering a progressive and fatal ...

This type is an autosomal dominant disease ... Various forms of hereditary amyloidosis have been described: transthyretin (ATTR), apolipoprotein (AApo) AI, AApoAII, gelsolin, fibrinogen Aa ...

The European Commission has granted marketing authorization in the European Union (EU) for acoramidis, under the brand name ...

This aligns with the broader trend of utilizing gene silencers and kinetic stabilizers to manage both hereditary and wild-type forms of ATTR amyloidosis, which has opened new avenues for treatment[4].

Alnylam’s (ALNY) treatment of transthyretin-mediated amyloidosis, or ATTR amyloidosis, was granted FDA orphan designation, according to a post ...

People with transthyretin cardiac amyloidosis (ATTR-CA ... (Attruby), another TTR stabilizer for treating wild-type or variant ATTR-CM. During the study period covered by Masri and colleagues ...

Pharma announced the European Commission has granted marketing authorization in the European Union for acoramidis, under the ...